Clinical observation of stable moderate and severe COPD on the treatment of tiotropium bromide inhalation combined seretide for patients

Objective To observe the therapeutic effect of inhaled tiotropium combined seretide in patients with stable moderate to severe chronic obstructive pulmonary disease(COPD).Methods 45 patients with stable moderate to severe COPD patients(completion of the pilot,43 cases out of experiment 2 because of sicker patients)were randomly divided into two groups:treatment group given tiotropium bromide(trade name:spiriva)and seretide(salmeterol,special Luo / fluticasone)inhalation for 12 weeks,control group was given 12 weeks of inhalation treatment seretide,and clinical symptoms,signs,oxygen saturation and pulmonary function key indicators were compared between the two groups before and after the treatment.Results Compared with the control group,FEV1/FVC and FEV1 of the treatment group accounting for percentage of predicted value significantly improved,and the clinical symptoms and signs and blood oxygen saturation improved significantly(P0.05).Conclusion Tiotropium bromide inhalation combined seretide is effective in improving lung function and can alleviate the clinical symptoms.